Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitroReport as inadecuate




Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro - Download this document for free, or read online. Document in PDF available to download.

BMC Developmental Biology

, 7:11

First Online: 21 February 2007Received: 26 July 2006Accepted: 21 February 2007

Abstract

BackgroundTerm Amniotic membrane AM is a very attractive source of Mesenchymal Stem Cells MSCs due to the fact that this fetal tissue is usually discarded without ethical conflicts, leading to high efficiency in MSC recovery with no intrusive procedures. Here we confirmed that term AM, as previously reported in the literature, is an abundant source of hMSCs; in particular we further investigated the AM differentiation potential by assessing whether these cells may also be committed to the angiogenic fate. In agreement with the recommendation of the International Society for Cellular Therapy, the mesenchymal cells herein investigated were named Amniotic Membrane-human Mesenchymal Stromal Cells AM-hMSC.

ResultsThe recovery of hMSCs and their in vitro expansion potential were greater in amniotic membrane than in bone marrow stroma. At flow cytometry analysis AM-hMSCs showed an immunophenotypical profile, i.e., positive for CD105, CD73, CD29, CD44, CD166 and negative for CD14, CD34, CD45, consistent with that reported for bone marrow-derived MSCs. In addition, amniotic membrane-isolated cells underwent in vitro osteogenic von Kossa stain, adipogenic Oil Red-O stain, chondrogenic collagen type II immunohistochemichal detection and myogenic RT-PCR MyoD and Myogenin expression as well as desmin immunohistochemical detection differentiation. In angiogenic experiments, a spontaneous differentiation into endothelial cells was detected by in vitro matrigel assay and this behaviour has been enhanced through Vascular Endothelial Growth Factor VEGF induction. According to these findings, VEGF receptor 1 and 2 FLT-1 and KDR were basally expressed in AM-hMSCs and the expression of endothelial-specific markers like FLT-1 KDR, ICAM-1 increased after exposure to VEGF together with the occurrence of CD34 and von Willebrand Factor positive cells.

ConclusionThe current study suggests that AM-hMSCs may emerge as a remarkable tool for the cell therapy of multiple diseased tissues. AM-hMSCs may potentially assist both bone and cartilage repair, nevertheless, due to their angiogenic potential, they may also pave the way for novel approaches in the development of tissue-engineered vascular grafts which are useful when vascularization of ischemic tissues is required.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-213X-7-11 contains supplementary material, which is available to authorized users.

Francesco Alviano, Valentina Fossati contributed equally to this work.

Download fulltext PDF



Author: Francesco Alviano - Valentina Fossati - Cosetta Marchionni - Mario Arpinati - Laura Bonsi - Michele Franchina - Giacomo Lan

Source: https://link.springer.com/article/10.1186/1471-213X-7-11



DOWNLOAD PDF




Related documents